Novel Drug Delivery System

A drug delivery system is a device or system that is used to administer a medication to a patient. Drug delivery systems can be used to deliver medicines through various routes, including oral, inhalation, intravenous, transdermal, and intramuscular. VMRC's Novel Drug Delivery System (NDDS) team is focused on developing drug delivery for cancer treatment. Drug-Protein-Polymer-Conjugate (DPPC) is the new triple conjugate concept designed for this purpose. Depending on the target organ, the specific DPPC component is selected. There are three types of drug delivery systems i.e., oral delivery, injectible delivery, and transdermal delivery. Oral delivery is the most common administered through tablets, capsules, and liquids. Intramuscular injections, subcutaneous injections, and intravenous injections are used for injectable deliveries. Transdermal drug delivery systems include patches, gels, and creams. A novel drug delivery system (DDS) is a promising new way to deliver drugs to patients. This system can help improve the efficacy of medications, reduce side effects, and improve patient compliance.

The team is working on target-based drug delivery for cancer treatment. The Company has designed a platform technology with a novel concept of triple conjugate i.e., Drug-Protein-Polymer-Conjugate (DPPC) for the purpose. Based on the specificity of the target organ, various components of DPPC can be rationally selected.

• Highly target specific and selective drug delivery system to a defined population of cells/organ(s) for chronic disease therapy like cancer.
• Minimized uptake of an active drug, by normal cells and enhances the influx and retention of the drug in target cells/ tissues/ organs.
• It provides a pharmaceutical formulation that is administered as a single unit dose through the IV route of the administration having better patient compliance.
• Lower dose and reduced frequency of the administration of a drug in comparison to individual use of the drug or known drug-polymer or known protein-polymer conjugate.
• Improved availability of the drug molecule at the target site and reduction in side effects due to targeted delivery and sustained release.